Haitham Mutlak1, Christian Rehse1, Bertram Scheller1, Peter Stein1, Andreas Pape1, Nestoras Papadopoulos2, Elisabeth Hannah Adam1, Christian Friedrich Weber1
1 Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Germany
2 Department of Thoracic and Cardiovascular Surgery, University Hospital Frankfurt, Germany
[Applied Cardiopulmonary Pathophysiology 17: 275-283, 2013]
Background: The manufacturer of the Multiplate® device recommends usage of lepirudin anticoagulated blood samples. It was the aim of the present study to analyze a potential relationship between blood samples that were drawn into lepirudin versus heparin anticoagulated tubes.
Methods: In a prospective cohort, single-center study, patients scheduled for elective coronary artery bypass grafting were preoperatively screened for eligibility. Patients were enrolled into the study if they had ceased any antiplatelet therapy for at least five days prior to the planned surgical intervention. Lepirudin and heparin anticoagulated blood samples were taken at the evening before surgery (T1), 4 h after the first postoperative ingestion of 100 mg aspirin (T2) and five days after begin of daily aspirin therapy (T3).
Results: n = 75 patients were finally enrolled into the study. There was a significant correlation between lepirudin and heparin anticoagulated samples at each measuring point. Platelet aggregability was higher in lepirudin anticoagulated blood as compared to heparin anticoagulated blood.
Conclusions: Data of the present study show that heparin anticoagulated blood samples are suitable for the assessment of arachidonic acid induced platelet aggregation of unaffected platelets as well as platelets with aspirin associated reduced aggregability.
Key words: Heparin, Multiplate, Multiple Electrode Aggregometry, Platelet function testing, Point-of-Care
PD Dr. Christian Weber
University Hospital Frankfurt
Department of Anesthesia, Intensive Care Medicine and Pain Therapy